Benjamin Daniel Malkin, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 7901 Broadway, Elmhurst Hospital Center, Elmhurst, NY 11373 Phone: 718-334-3392 Fax: 718-334-5886 |
Michael A. Rothschild, MD Otolaryngology - Pediatric Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 7901 Broadway, Room A1 - 9, Elmhurst, NY 11373 Phone: 718-334-4952 Fax: 718-334-4815 |
Dr. Leao A. Pereira, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 88-06 55th Ave, Elmhurst, NY 11373 Phone: 718-899-6600 Fax: 718-397-7782 |
News Archive
Misonix, Inc., an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announces that it has once again supported the Uganda Spine Surgery Mission organized by leading spine surgeon Dr. Isador Lieberman, from the Texas Back Institute in Plano, TX, by providing an ultrasonic BoneScalpel for use in a number of advanced spinal surgeries.
A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo.
EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has received a cash injection of EUR 2 million from existing shareholders.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabineā¢, for the treatment of AML.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
› Verified 9 days ago